Drugs / NOX-E36
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01372124 | Jun 2011 → Oct 2012 | impaired renal function disease | TME Pharma AG | Completed | No outcome recorded |
| Phase 1 | NCT00976729 | May → Dec 2009 | systemic lupus erythematosus, type 2 diabetes mellitus | TME Pharma AG | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01085292 | Jul 2010 → Feb 2012 | type 2 diabetes mellitus | TME Pharma AG | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01547897 Comparator | Mar 2012 → Sep 2013 | proteinuria, type 2 diabetes mellitus | TME Pharma AG | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-03-13 | TME Pharma AG | Results TME Pharma announces filing of patents for use of CCL2 inhibitor NOX-E36 in ophthalmology and presentation at ARVO 2025 of preclinical data showing benefit in glaucoma filtration surgery tmepharma.com ↗ |
| 2019-02-01 | TME Pharma AG | Results New data published supporting monotherapy activity of CCL2 inhibitor NOX-E36 in an additional solid tumor type: liver cancer tmepharma.com ↗ |
All press releases naming this drug 6 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NOX E36 | “All subjects included in this study will receive the same dose of NOX E36.” NCT01372124 ↗ |
| Modality | Aptamer | “the Spiegelmer® NOX-E36” NCT01547897 ↗ |
| Route | Intravenous | “single intravenous (IV) and subcutaneous (SC) doses” NCT00976729 ↗ |
| Route | Subcutaneous | “single intravenous (IV) and subcutaneous (SC) doses” NCT00976729 ↗ |